2863 related articles for article (PubMed ID: 7646914)
41. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
Guida M; Latorre A; Mastria A; De Lena M
Eur J Cancer; 1996 Apr; 32A(4):730-3. PubMed ID: 8695281
[TBL] [Abstract][Full Text] [Related]
42. A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
Gause BL; Sharfman WH; Janik JE; Curti BD; Steis RG; Urba WJ; Smith JW; Alvord WG; Longo DL
Cancer Invest; 1998; 16(6):374-80. PubMed ID: 9679527
[TBL] [Abstract][Full Text] [Related]
43. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Feun L; Marini A; Moffat F; Savaraj N; Hurley J; Mazumder A
Cancer Invest; 2005; 23(1):3-8. PubMed ID: 15779861
[TBL] [Abstract][Full Text] [Related]
44. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
Schomburg A; Kirchner H; Atzpodien J
Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
[TBL] [Abstract][Full Text] [Related]
45. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.
Antoine EC; Benhammouda A; Bernard A; Youssef A; Mortier N; Gozy M; Nizri D; Auclerc G; Rocher MA; Soubrane CL; Weil M; Khayat D
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S16-21. PubMed ID: 9457388
[TBL] [Abstract][Full Text] [Related]
46. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
[TBL] [Abstract][Full Text] [Related]
47. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring.
Dummer R; Gore ME; Hancock BW; Guillou PJ; Grobben HC; Becker JC; Oskam R; Dieleman JP; Burg G
Cancer; 1995 Feb; 75(4):1038-44. PubMed ID: 7842406
[TBL] [Abstract][Full Text] [Related]
48. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
[TBL] [Abstract][Full Text] [Related]
49. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
50. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
[TBL] [Abstract][Full Text] [Related]
51. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
[TBL] [Abstract][Full Text] [Related]
52. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
[TBL] [Abstract][Full Text] [Related]
53. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
54. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
[TBL] [Abstract][Full Text] [Related]
56. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Groenewegen G; Bloem A; De Gast GC
Cancer Immunol Immunother; 2002 Dec; 51(11-12):630-6. PubMed ID: 12439608
[TBL] [Abstract][Full Text] [Related]
57. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
[TBL] [Abstract][Full Text] [Related]
58. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
Bajetta E; Del Vecchio M; Vitali M; Martinetti A; Ferrari L; Queirolo P; Sertoli MR; Cainelli T; Cellerino R; Cascinelli N
Tumori; 2001; 87(4):219-22. PubMed ID: 11693798
[TBL] [Abstract][Full Text] [Related]
59. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
[TBL] [Abstract][Full Text] [Related]
60. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]